370 related articles for article (PubMed ID: 27249746)
1. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
Rugo HS; Vidula N; Ma C
Am Soc Clin Oncol Educ Book; 2016; 35():e40-54. PubMed ID: 27249746
[TBL] [Abstract][Full Text] [Related]
2. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
3. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
[TBL] [Abstract][Full Text] [Related]
4. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
6. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
Saatci O; Huynh-Dam KT; Sahin O
J Mol Med (Berl); 2021 Dec; 99(12):1691-1710. PubMed ID: 34623477
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Johnston SR
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
[TBL] [Abstract][Full Text] [Related]
8. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Bøttcher TM; Cold S; Jensen AB
Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Kim ES; Scott LJ
Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
[TBL] [Abstract][Full Text] [Related]
11. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
AlFakeeh A; Brezden-Masley C
Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
[TBL] [Abstract][Full Text] [Related]
12.
Drago JZ; Formisano L; Juric D; Niemierko A; Servetto A; Wander SA; Spring LM; Vidula N; Younger J; Peppercorn J; Yuen M; Malvarosa G; Sgroi D; Isakoff SJ; Moy B; Ellisen LW; Iafrate AJ; Arteaga CL; Bardia A
Clin Cancer Res; 2019 Nov; 25(21):6443-6451. PubMed ID: 31371343
[TBL] [Abstract][Full Text] [Related]
13. Acquired HER2 mutations in ER
Nayar U; Cohen O; Kapstad C; Cuoco MS; Waks AG; Wander SA; Painter C; Freeman S; Persky NS; Marini L; Helvie K; Oliver N; Rozenblatt-Rosen O; Ma CX; Regev A; Winer EP; Lin NU; Wagle N
Nat Genet; 2019 Feb; 51(2):207-216. PubMed ID: 30531871
[TBL] [Abstract][Full Text] [Related]
14. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
15. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Sharifi MN; Anandan A; Grogan P; O'Regan RM
Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
Perez EA
Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
[TBL] [Abstract][Full Text] [Related]
17. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
18. [Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer].
Boér K
Magy Onkol; 2017 Jun; 61(2):167-173. PubMed ID: 28585619
[TBL] [Abstract][Full Text] [Related]
19. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutical strategies in metastatic hormone-dependent breast cancer].
Vilquin P; Cohen P; Maudelonde T; Tredan O; Treilleux I; Bachelot T; Heudel PE
Bull Cancer; 2015 Apr; 102(4):367-80. PubMed ID: 25799877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]